C27Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEPOn-demand oral abstract sessionPrEP
C27SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine- based PrEP in 2020 ' a sub-study of PREVENIR-ANRS and SAPRIS-SeroOn-demand oral abstract sessionPrEP
C27Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019 ' June 2020On-demand oral abstract sessionPrEP
C27Uptake of oral pre-exposure prophylaxis for HIV infection among men who have sex with men and transgender: lessons learned during the SARS-CoV-2 pandemic from the first PrEP project in MyanmarOn-demand oral abstract sessionPrEP
C27HIV risk behaviors among retail pharmacy clients seeking sexual and reproductive health services in KenyaOn-demand oral abstract sessionPrEP
C27STI incidence among participants in the HIV Pre-exposure Prophylaxis (PrEP) impact trial in EnglandOn-demand oral abstract sessionPrEP
C27Safety and pharmacokinetics of oral islatravir once monthly for HIV pre-exposure prophylaxis (PrEP): week 24 analysis of a phase 2a trialOral abstract session with live Q&APrEP
C27Outcomes of participants switching from F/TDF to F/TAF for PrEP: week 48 results from the DISCOVER open label phaseOral abstract session with live Q&APrEP
C27Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the USOral abstract session with live Q&APrEP
C27Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators, and preferences for PrEP use among MSM and TGWOral abstract session with live Q&APrEP
481 - 490 of 870 items